Page 111 - IMO-1-1

Innovative Medicines & Omics SARS-CoV-2 inhibition by quinolines

Res Pract. 2010;2010:394578. ferroquine is an inhibitor of hepatitis C virus. Hepatology.
2013;58(1):86-97.
doi: 10.1155/2010/394578
doi: 10.1002/hep.26273
45. Kumar S, Sarma P, Kaur H, et al. Clinically relevant
cell culture models and their significance in isolation, 56. Marois I, Cloutier A, Meunier I, et al. Inhibition of influenza
pathogenesis, vaccine development, repurposing and virus replication by targeting broad host cell pathways. PLoS
screening of new drugs for SARS-CoV-2: A systematic One. 2014;9(10):e110631.
review. Tissue Cell. 2021;70:101497.
doi: 10.1371/journal.pone.0110631
doi: 10.1016/j.tice.2021.101497
57. Ribeiro Antinarelli LM, Glanzmann N, Mendonça DV,
46. Prieto Santamaría L, Díaz Uzquiano M, Ugarte Carro E, et al. Parasitological and immunological evaluation of a
Ortiz-Roldán N, Pérez Gallardo Y, Rodríguez-González A. quinoline derivative salt incorporated into a polymeric
Integrating heterogeneous data to facilitate COVID-19 drug micelle formulation against Leishmania infantum infection.
repurposing. Drug Discov Today. 2022;27(2):558-566. Parasitol Res. 2022;121(7):2129-2140.
doi: 10.1016/j.drudis.2021.10.002 doi: 10.1007/s00436-022-07544-1
47. Siminea N, Popescu V, Sanchez Martin JA, et al. Network 58. De Souza NB, Carmo AM, Lagatta DC, et al. 4-aminoquinoline
analytics for drug repurposing in COVID-19. Brief analogues and its platinum (II) complexes as antimalarial
Bioinform. 2022;23(1):bbab490. agents. Biomed Pharmacother. 2011;65(4):313-316.
doi: 10.1093/bib/bbab490 doi: 10.1016/j.biopha.2011.03.003
48. Sezer A, Halilović-Alihodžić M, Vanwieren AR, et al. 59. De Souza NB, Carmo AM, Da Silva AD, et al. Antiplasmodial
A review on drug repurposing in COVID-19: From activity of chloroquine analogs against chloroquine-resistant
antiviral drugs to herbal alternatives. J Genet Eng Biotechnol. parasites, docking studies and mechanisms of drug action.
2022;20(1):78. Malar J. 2014;13(1):469.
doi: 10.1186/s43141-022-00353-0 doi: 10.1186/1475-2875-13-469
49. Sinha N, Balayla G. Hydroxychloroquine and COVID-19. 60. Bezerra Bellei JC, Glanzmann N, Carpinter BA, et al.
Postgrad Med J. 2020;96(1139):550-555. A simple quinoline salt derivative is active in vitro against
Plasmodium falciparum asexual blood stages and inhibits
doi: 10.1136/postgradmedj-2020-137785
the development of cerebral malaria in murine model. Chem
50. Yuan Z, Pavel MA, Wang H, et al. Hydroxychloroquine Biol Interact. 2022;355:109848.
blocks SARS-CoV-2 entry into the endocytic pathway in doi: 10.1016/j.cbi.2022.109848
mammalian cell culture. Commun Biol. 2022;5(1):958.
61. Zhang Q, Xiang R, Huo S, et al. Molecular mechanism
doi: 10.1038/s42003-022-03841-8
of interaction between SARS-CoV-2 and host cells and
51. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic interventional therapy. Signal Transduct Target Ther.
derivative of chloroquine, is effective in inhibiting SARS- 2021;6(1):233.
CoV-2 infection in vitro. Cell Discov. 2020;6(1):16.
doi: 10.1038/s41392-021-00653-w
doi: 10.1038/s41421-020-0156-0
62. Essalmani R, Jain J, Susan-Resiga D, et al. Distinctive roles
52. Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M. of furin and TMPRSS2 in SARS-CoV-2 infectivity. J Virol.
Hydroxychloroquine-mediated inhibition of SARS- 2022;96(8):e0012822.
CoV-2 entry is attenuated by TMPRSS2. PLoS Pathog.
2021;17(1):e1009212. doi: 10.1128/jvi.00128-22
63. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms
doi: 10.1371/journal.ppat.1009212
of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol.
53. Biot C, Glorian G, Maciejewski LA, Brocard JS. Synthesis and 2022;23(1):3-20.
antimalarial activity in vitro and in vivo of a new ferrocene- doi: 10.1038/s41580-021-00418-x
chloroquine analogue. J Med Chem. 1997;40(23):3715-3718.
64. Shapira T, Monreal IA, Dion SP, et al. A TMPRSS2 inhibitor
doi: 10.1021/jm970401y
acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
54. Biot C, Daher W, Chavain N, et al. Design and synthesis Nature. 2022;605(7909):340-348.
of hydroxyferroquine derivatives with antimalarial and doi: 10.1038/s41586-022-04661-w
antiviral activities. J Med Chem. 2006;49:2845-2849.
65. Aiewsakun P, Phumiphanjarphak W, Ludowyke N, et al.
doi: 10.1021/jm0601856
Systematic exploration of SARS-CoV-2 adaptation to
55. Vausselin T, Calland N, Belouzard S, et al. The antimalarial vero e6, vero E6/TMPRSS2, and calu-3 cells. Genome Biol

Volume 1 Issue 1 (2024) 105 doi: 10.36922/imo.3442